Volta Medical, the developer of AI solutions to assist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), has received €36 million in new Series B funding, bringing the total capital raised to over €70 million.
The round was led by Vensana Capital with co-investment from Lightstone Ventures and existing investor, Gilde Healthcare.
The funding will support product development and additional clinical trials, prepare the company for full-scale US commercialisation and enable it to pursue further regulatory approvals.
Volta’s lead product, VOLTA VX1, is the first commercially available AI decision-support software to help physicians identify unique abnormalities on 3D anatomical and electrical maps of the heart.
Volta Medical CEO and co-founder, Theophile Mohr Durdez, said:
“There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF.
“With half of these patients requiring repeat treatments, clinicians need tools that enable them to better understand the disease and drastically improve patient outcomes.
“We believe VOLTA’s VX1 has the potential to do just that in a consistent, reproducible way.
“We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.”
Volta Medical has also announced the appointment of John Slump as CFO.
Slump has led multiple MedTech companies from concept through regulatory approvals, commercial growth and strategic acquisitions.
Most recently, he served as CFO of Surgical Innovation Associates which was acquired by Integra LifeSciences.
Prior to that, Slump co-founded FARAPULSE – a medical device company pioneering novel pulsed field ablation technology that was acquired in Boston Scientific in 2021.
Slump said:
“I’m excited to join the Volta Medical team and am pleased with our ability to attract significant equity investment from both new and existing investors in an increasingly challenging fundraising climate.
“VOLTA VX1 has the potential to make a major difference in the lives of millions of people with AF, and this Series B Financing will help to accelerate its development and adoption nationally and across the globe.”
